Mustafa Suker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6192920/publications.pdf

Version: 2024-02-01

471371 377752 3,498 35 17 34 citations h-index g-index papers 36 36 36 3982 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncology, The, 2016, 17, 801-810.	5.1	719
2	Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. Journal of Clinical Oncology, 2020, 38, 1763-1773.	0.8	665
3	Minimally Invasive Versus Open Distal Pancreatectomy (LEOPARD). Annals of Surgery, 2019, 269, 2-9.	2.1	401
4	Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 199-207.	3.7	393
5	Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. Journal of Clinical Oncology, 2022, 40, 1220-1230.	0.8	274
6	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Journal of the National Cancer Institute, 2019, 111, 782-794.	3.0	223
7	The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels. Annals of Surgery, 2019, 270, 139-146.	2.1	179
8	Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. Trials, 2016, 17, 127.	0.7	131
9	Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial Journal of Clinical Oncology, 2018, 36, LBA4002-LBA4002.	0.8	120
10	Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib. Theranostics, 2016, 6, 1821-1832.	4.6	100
11	Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial). EClinicalMedicine, 2019, 17, 100200.	3.2	41
12	Low skeletal muscle mass is associated with increased hospital expenditure in patients undergoing cancer surgery of the alimentary tract. PLoS ONE, 2017, 12, e0186547.	1.1	38
13	Preoperative chemoradiotherapy to improve overall survival in pancreatic cancer: Long-term results of the multicenter randomized phase III PREOPANC trial Journal of Clinical Oncology, 2021, 39, 4016-4016.	0.8	33
14	Surgical Complications in a Multicenter Randomized Trial Comparing Preoperative Chemoradiotherapy and Immediate Surgery in Patients With Resectable and Borderline Resectable Pancreatic Cancer (PREOPANC Trial). Annals of Surgery, 2022, 275, 979-984.	2.1	26
15	Pancreatic cancer treated with SBRT: Effect of anatomical interfraction variations on dose to organs at risk. Radiotherapy and Oncology, 2019, 134, 67-73.	0.3	23
16	Pathological validation and prognostic potential of quantitative MRI in the characterization of pancreas cancer: preliminary experience. Molecular Oncology, 2020, 14, 2176-2189.	2.1	23
17	Yield of staging laparoscopy before treatment of locally advanced pancreatic cancer to detect occult metastases. European Journal of Surgical Oncology, 2019, 45, 1906-1911.	0.5	22
18	FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study. Journal of Surgical Oncology, 2018, 118, 1021-1026.	0.8	20

#	Article	IF	Citations
19	Patient Satisfaction and Quality of Life Before and After Treatment of Pancreatic and Periampullary Cancer: A Prospective Multicenter Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 704-711.	2.3	14
20	The Dutch Pancreas Biobank Within the Parelsnoer Institute. Pancreas, 2018, 47, 495-501.	0.5	8
21	Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer. Strahlentherapie Und Onkologie, 2017, 193, 630-638.	1.0	7
22	Patients with chronic mesenteric ischemia have an altered sublingual microcirculation. Clinical and Experimental Gastroenterology, 2018, Volume 11, 405-414.	1.0	5
23	High Systemic Immune Inflammation Index Is Associated With Low Skeletal Muscle Quantity in Resectable Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology, 2022, 12, 827755.	1.3	5
24	Are a Double Duct Sign or Endoscopic Biopsies Reliable Predictors of Malignancy in Periampullary Lesions. Digestive Surgery, 2015, 32, 306-311.	0.6	4
25	Sublingual microcirculation in pancreatico-biliary surgery: An observational study. Clinical Hemorheology and Microcirculation, 2019, 72, 247-257.	0.9	4
26	Immune-Related Circulating miR-125b-5p and miR-99a-5p Reveal a High Recurrence Risk Group of Pancreatic Cancer Patients after Tumor Resection. Applied Sciences (Switzerland), 2019, 9, 4784.	1.3	4
27	External Validity of the Multicenter Randomized PREOPANC Trial on Neoadjuvant Chemoradiotherapy in Pancreatic Cancer. Annals of Surgery, 2020, Publish Ahead of Print, .	2.1	4
28	The yield of chest computed tomography in patients with locally advanced pancreatic cancer. Journal of Surgical Oncology, 2020, 122, 450-456.	0.8	3
29	Preoperative serum ADAM12 levels as a stromal marker for overall survival and benefit of adjuvant therapy in patients with resected pancreatic and periampullary cancer. Hpb, 2021, 23, 1886-1896.	0.1	3
30	Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis Journal of Clinical Oncology, 2018, 36, e16207-e16207.	0.8	2
31	Sa2021 Patients With Chronic Gastrointestinal Ischemia Have an Altered Sublingual Microcirculation. Gastroenterology, 2016, 150, S431-S432.	0.6	1
32	Pancreatic Duct Obstruction in a Middle-Aged Woman: A Case Report. Journal of Pancreatic Cancer, 2017, 3, 13-14.	1.6	1
33	A Rare Tumor in the Common Bile Duct: A Case Report. Journal of Pancreatic Cancer, 2017, 3, 10-12.	1.6	1
34	Daily dose to organs at risk predicts acute toxicity in pancreatic stereotactic radiotherapy. Acta Oncol \tilde{A}^3 gica, 2020, 59, 944-948.	0.8	1
35	Pancreatic Duct Obstruction in a Middle-Aged Woman: A Case Report. Journal of Pancreatic Cancer, 2017, 3, 13-14.	1.6	0